ClinicalTrials.gg

Program

Triamcinolone

Also written as “intravitreal triamcinolone injection”, “Triamcinolone (Optional)” and “Triamcinolone Injection”.

Its studies are mostly in Cataract · Acne Vulgaris · Melanosis · Macular Edema · Rhinitis, Allergic, Perennial, led by 4 companies.

Furthest: phase 4, since Dec 6, 20234 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ACOM Labs10 open or runningno phasesince Dec 6, 2023Dec 6, 2023none ahead
Research Insight11 open or runningphase 4since Oct 30, 2025Oct 30, 2025Dec 31, 2026phase 4 · NCT07276802
Sanofi10 open or runningphase 3since Aug 18, 2005Aug 18, 2005none ahead
The Emmes10 open or runningphase 3since Mar 3, 2005Mar 3, 2005none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2005First study: phase 3 study in Macular EdemaNew to The EmmesThe Emmes · NCT00105027 · 682 enrolled · United States
  2. Aug 18, 2005Sanofi's first study: phase 3 study in Rhinitis, Allergic, PerennialNew to SanofiSanofi · NCT00132925 · 460 enrolled · United States
  3. Dec 6, 2023ACOM Labs's first study: no phase study in Acne VulgarisNew to ACOM LabsACOM Labs · NCT06170593 · 20 enrolled · United States
  4. Oct 30, 2025Research Insight's first study: phase 4 study in Post Cataract SurgeryNew to Research InsightResearch Insight · NCT07276802 · 40 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 4 study in Post Cataract SurgeryResearch Insight · NCT07276802

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07276802Post Cataract Surgery · United States4Not yet recruitingResearch InsightDec 31, 202640
NCT06170593Acne Vulgaris · United States–CompletedACOM LabsJan 31, 202320
NCT00132925Rhinitis, Allergic, Perennial · United States3CompletedSanofi460
NCT00105027Macular Edema · United States3CompletedThe EmmesFeb 2009682

How it is read

Names in the registry

  • “intravitreal triamcinolone injection”, 2 entries
  • “Triamcinolone (Optional)”, 1 entry
  • “Triamcinolone Injection”, 1 entry
  • “arbutin, tretinoin, triamcinolone”, 1 entry
  • “Triamcinolone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.